InvivoCrown-Flyer

In immunology and the field of cell and gene therapy (CGT), selective elimination of defined cell populations—commonly referred to as cell depletion—is a widely adopted strategy to interrogate the functional roles of specific cellular subsets and their associated molecular targets.

Complement component 5(C5) is a central hub of the complement cascade, with a molecular weight of approximately 190 kDa, composed of an α-chain (111 kDa) and a β-chain (75 kDa) linked by disulfide bonds. Upon cleavage by C5 convertase, C5 generates two potent effector molecules: C5a, a highly active anaphylatoxin and chemoattractant that drives the recruitment and activation of neutrophils and monocytes; and C5b, which initiates the formation of the membrane attack complex (MAC, C5b-9) leading to target cell lysis. Therefore, blocking C5 simultaneously inhibits terminal complement activation and downstream inflammatory signaling, while preserving upstream C3b-mediated opsonization—making C5

Executive SummaryThis standardized protocol provides evidence-based guidance for the intraperitoneal (IP) administration of InvivoPro Anti-Mouse PD-1 (CD279) Antibody (Clone RMP1-14, Cat. No. IV0100) in preclinical mouse models. Developed from aggregated indep